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Abstract 
Background: COPD, a progressive, partly reversible condition with airflow limitation particularly warrants 
the   inclusion of pharmacists in the healthcare team. Extreme physician scarcity severely limits the 
implementation of quality healthcare in India. Pharmacist-led educational intervention achieves smoking 
cessation and improves medication adherence.  Objective: This study evaluated the effectiveness of a 
clinical pharmacist-led intervention on medication adherence in COPD patients in a teaching hospital. 
Methods: In an open-labelled randomized controlled study at Kasturba Medical College Hospital, Manipal, 
India, patients were randomly assigned to two groups (Intervention group [IG] and Control group [CG]), 
and were matched for socio-demographics and clinical characteristics.  Medication adherence was 
assessed by the Morisky, Green and Levine Medication Adherence Questionnaire (MAQ). In IG, 
pharmacist intervention placed emphasis on (1) compliance, (2) smoking cessation, (3) exercise, (4) 
inhaler use and (5) need for timely follow up. The MAQ assessment was repeated at 6, 12, 18 and 24 
months. Data were analysed statistically by SPSS version 20.0. Results: Out of 328 patients screened 
during March 2012 to June 2013, 260 were recruited. Of these, 206 completed the follow-up (98 in CG 
and 104 in IG). Medication adherence improved significantly after pharmacist intervention in IG at all 
follow-up time points (P<0.001). It increased from 49% at the baseline to 80% after 24 months (P<0.001). 
Carelessness about taking medicines was one of the main reasons for non-adherence in COPD patients, 
but was effectively reduced by the intervention.  Conclusions: This is the first randomized controlled trial 
in India that demonstrates the pivotal role of pharmacist-led educational intervention in improving 
medication adherence in COPD. Involving non-physician health professionals could be the best strategy, 
for resource-poor nations like India, because the current physician-centric healthcare has no emphasis on 
patient education and counseling. 
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Introduction 
 
Chronic obstructive pulmonary disease (COPD) is characterised by a progressive airflow limitation in the 
lungs, which, unlike asthma, is not fully reversible by medication.1 However, adherence to therapy 
improves the management of symptoms and delays disease progression.2 3DWLHQWV¶NQRZOHGJHDQG
awareness about the disease are also important in leading a normal life. Overall, it is estimated that the 
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number of people aged 30 and over worldwide with COPD is estimated at 384 million, with a prevalence 
of 11.7% (8.4%±15.0%).3 The Global Burden of Disease Study revealed that COPD is the fourth leading 
cause of death worldwide, claimed 3.2 million lives in 2015,4 and projected to be the third leading cause 
by 2030.5  In addition to its impact on mortality, COPD is also associated with an appreciable impact on 
morbidity and costs.2,6,7-9 Consequently, it is a high priority area to focus on. 
 
Adherence to medication therapy is considered a major concern. $GKHUHQFHLVGHILQHGDV³WKHH[WHQWWR
ZKLFKDSHUVRQ¶VEHKDYLRULQWHUPVRIIROORZLQJGLHWVWDNLQJPHGLFDWLRQVRUH[HFXWLQJOLIHVW\OHFKDQJHV
coincides ZLWKPHGLFDORUKHDOWKDGYLFH´10 Patient non-adherence is one of the best recorded, but one of 
the least understood health-related behaviors.11 The lack of adherence to medications was described by 
the World Health Organization as ³DQHZSKDUPDFRORJLFDOSUREOHP´. 6 Moreover, substantially increasing 
the effectiveness of measures and interventions designed to increase patients¶ adherence to their 
therapies and recommendations may result in an LPSDFWRQSHRSOH¶VKHDOWKfar better than any other 
progress made in the therapeutic arena.6  
 
In COPD patients, non-adherence to medication in COPD is high, with some studies showing adherence 
rates to inhaled and oral medications between 41% to 57%. 2, 12-13 Adherence in clinical practice may be 
even lower at only 10% to 40% of patients with COPD. 14-15 Non-adherence with their treatment 
recommendations can be both intentional (such as, negative attitudes to medication-taking behavior, side 
effects, cost, does not feel sick, etc.) and unintentional, due to reasons related to forgetting, 
misunderstanding, problems remembering, failure to plan ahead, etc.16 In addition, there are concerns 
with inhaler technique which is typically seen as sub-optimal 2,17 with adherence adversely affected if 
patients are using different devices requiring different techniques.18 However, it is evident that better 
medication adherence is associated with decrease in the number of emergency department visits and 
length of hospital stay among patients with chronic respiratory diseases19 with improved adherence 
reducing costs.20 
 
Consequently, in order for a medication to be useful, not only should the active ingredient be effective, 
and its delivery must be optimal, but also patients¶ adherence to their medications is an essential factor 
for success of therapy.6 Intentional non-adherence is considered an active process in which patients 
decide not to fill their prescribed medications. It is estimated among patients with respiratory diseases 
that approximately 15% of patients do not fill a new prescription and usually discontinue therapy after 
approximately six months.6 In contrast, unintentional non-adherence is considered as a passive process, 
with patients failing to take their medications and follow therapy recommendations for many reasons 
outside their control including old age, financial inability to buy their medicines, affecting 20% to over 50% 
of patients.6  
 
In the literature, several studies have suggested that health professionals¶style of communication with the 
patient can affect the patient's ability and tendency to adhere to their medications.21 Although health 
professionals are increasingly aware that non-adherence is a major health issue, individual patients may 
not readily disclose their non-adherence without an intervention and assessments by their health 
providers. 21 Consequently, the role of health professionals is essential to encourage patients adherence 
to the therapeutic plan.2,6 For example, there is evidence that health professionals can encourage 
readiness to quit smoking. Wilson et al demonstrated that, even three-minutes of counselling can 
increase the rate of quitting by 5-10%.22 When different health professionals such as pharmacists, doctors 
and nurses jointly counsel patients, the impact is typically greater. To illustrate this, the rate of quitting of 
smoking was enhanced when 1,723 smokers received advise from different categories of health 
professionals (OR 2.37; 95% CI 1.15-4.88).23  
 
Providing adequate information about medications to the patients (e.g. indication of medication, clear 
instructions on medication use) improves adherence.2, 6 Providing tailored educational counseling raises 
the level of patient confidence, self efficacy, and improves their understanding on how to take their 
medications.24  
 
In COPD and asthma patients, it is estimated that over 50% of them struggle to use metered-dose 
inhalers (MDIs) correctly.25 Each medication with its inhaler has different characteristics in terms of (1) 
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internal resistance, (2) intra-thoracic deposition, (3) mechanism to check that the product was actually 
delivered, and (4) time and duration of action, affecting  adherence in practice.25 Manual dexterity and 
hand strength necessary to operate the inhaler is also important, especially in the elderly. 17 Poor inhaler 
technique DQGSDWLHQWV¶EHOLHIVDERXWLOOQHVVDUH associated with diminished quality of life. 11 The lack of 
perceived benefit from therapy has also been associated with 30% of patients with COPD intentionally 
discontinuing their therapy.26  
 
Whilst the exact burden of COPD in India is currently unknown5 although some studies have suggested 
prevalence rates of between 6.5% and 7.5% 27 prevalence rates for COPD are known to be appreciably 
higher in low and middle income countries such as India 2 Overall, China and India appear to account for 
66% of global COPD mortality.5,28 Alongside this appreciable burden, we are aware that there is currently 
very little published data on the impact of clinical pharmacist-led patient self-management in COPD in 
India. However, in other countries, published studies have shown that clinical pharmacist-led, continuous, 
individualized patient education that identifies and recognizes psychosocial components of patient 
behavior can enhance overall satisfaction with health care experience in patients with COPD.29-32 
Consequently, this study aimed to evaluate the effectiveness of a structured pharmacist- led intervention 
programme on medication adherence in COPD patients in India.  
 
Methodology: 
Study Design and Subjects: 
An open-labelled randomized controlled study was conducted at Kasturba Medical College Hospital, 
Manipal, India, over a 3 year period. Institutional ethical clearance (IEC 88/2012) was obtained prior to 
the study and registered with the Indian clinical trial registry (CTRI/2014/08/004848). The study subjects 
were selected based on inclusion criteria (confirmed diagnosis of COPD as per GOLD guidelines) and 
informed consent. Patients were randomized (envelop method) into two groups (Intervention group [IG] 
and Control group [CG]).   
 
Sample size:  
In accordance to published literature, we estimated the minimum sample size (based on measure of 
variation) of 100 in each group, in order to demonstrate minimum clinically significance of 5% (power 
=80%). Target sample size was estimated to be 260 patients (130 CG and 130 IG) taking into account a 
30% potential dropout rate.  
 
Baseline assessment:  
Baseline data for each patient was collected using a custom designed and validated case record form. 
The collected data included demographic measures, disease characteristics, respiratory and non-
respiratory medications and medication regimen. The patients were also asked to complete a self-
reported Morisky, Green and Levine Medication Adherence Questionnaire (MAQ).21 The reason for 
medication non-adherence was measured at baseline and at 24 months using a validated questionnaire.  
 
Follow up assessment:  
The medication adherence assessment was repeated at 6, 12, 18 and 24 months in both the groups.  
 
Study questionnaire: 
MAQ, which measures adherence through four Yes/No response items, accounts for the various reasons 
for non-adherence namely: forgetting, carelessness, stopping when feeling better and stopping when 
feeling worse. [Scoring :- µ<(6¶ 0µ12¶ 1]. Consequently, MAQ scores range between 0 and 4. Score 
of 3-4 considered as high adherence, 2 = moderate adherence and < 2 = low adherence.  
 
Structured Pharmacist Intervention:  
3DWLHQWV¶SHUFHSWLRQVZHUHFDSWXUHGDFFXUDWHO\E\RQHon one interviews, whenever the patients were 
comfortable. Patients recruited under IG were educated by the clinical pharmacist. The counselling 
sessions (15-20 minutes) and patient information leaflets (PILs) emphasised (1) the importance of 
medication compliance, (2) dose and frequency of medications, (3) need for smoking cessation, (4) 
simple exercise, (5) proper use of inhaler devices and (6) need for timely monitoring by the pulmonary 
medicine department. Each patient was followed up for a period of two years, and adherence was re-
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assessed after every six months. Patient information leaflets (PILs) describing the above techniques were 
developed, validated and supplied to patients for reinforcing the content delivered through counselling. 
Patients were further followed up by monthly telephone calls for ensuring medication adherence and 
timely follow ups. During follow up, patients in IG were trained for proper use of inhaler devices and were 
motivated for medication adherence.  
 
Control patients 
CG received standard hospital care, but did not receive the intervention by the clinical pharmacist.  
 
Development and validation of PILs: 
PILs were developed based on information collected from different sources VXFKDV³3DWLHQW8.´
Micromedex, GOLD guidelines, etc. The contents of the leaflet were validated and appropriately revised 
by physicians.  Readability of the designed PIL was calculated online (www.readability-score.com) by (1) 
Flesch Readability Ease (FRE) and (2) Flesch-Kincaid Grade Level (FK-GL). Baker Able Leaflets Design 
(BALD) was used to assess layout and design characteristics of the PILs. The details regarding 
development and validation of these PILs are published elsewhere. 33  
 
Data analysis:  
SPSS version 20.0 were used for statistical analyses (Data screening, descriptive statistics and univariate 
analysis). Chi square analysis was performed to assess the significance (between CG and IG) in MAQ. A 
P- value of <0.05 was considered statistically significant. 
 
Results 
 
The present study was carried out as part of a larger study on the impact of pharmaceutical care on 
outcomes in COPD patients.34  
Participants Flow 
 
Out of 328 COPD patients screened during the study period (March 2012 to June 2013), 260 were 
recruited. Of these, 206 patients completed follow up (98 in CG and 104 in IG). Reasons for drop out, in 
the decreasing order of importance were (a) lost to follow up (18 in CG and 11 in IG) (b) death (8 in CG vs 
9 in IG) (c) withdrawal at different level of the study (5 in CG vs 3 in IG). Fig. 1 is a flow chart indicating 
patient numbers at different level of the study. 
 
Figure 1: Flow chart indicating patient numbers at different stages of the study 
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Baseline characteristics of study population: 
CG and IG were matched (P>0.05) for baseline socio-demographic and clinical characteristics such as (a) 
mean age (61.1±8.4 vs 60.6±7.9), (b) male gender (94.4 vs 96.9) (c) Duration of COPD (15.3±5.7 vs 
14.6±6.6), (d) Mean FEV1 (41.9±14.7 vs 44.4±14.5), (e) Average number of drugs used (7.2±2.1 vs 
6.3±1.7), (f) co-morbidity rate (74% vs 69%), (g) current smokers (53.8% vs 56.9%). As per 
.XSSXVZDP\¶VVRFLRHFRQRPLFFODVVLILFDWLRQ 35 majority belonged to upper lower category in both groups 
(UG=30.5% vs IG=29.8%). Pack years was estimated to be 21.7±12.6 in CG and 23.2±11.4 in IG.  
Majority of the patients belongs to GOLD III (severe) category (45.4 vs 47.6). The baseline characteristics 
of the study population are described in Table 1. 
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Table 1: Baseline characteristics of study population 
 
Characteristics CG IG P-value 
Age (Mean±SD)  61.1±8.4 60.6±7.9 0.67 
Gender (Male, %) Á 94.4 96.9 0.08 
Socioeconomic status 18 (%) Á 0.73 
    Lower 35.8 37.4  
    Upper lower 30.5 29.8  
    Middle 23.7 20.6  
    Upper middle 7.1 6.4  
    Upper  2.9 5.8  
FEV1 % predicted¶ (Mean±SD)  41.9±14.7 44.4±14.5 0.16 
Smoking Status (%) Á 0.24 
    Ex-Smoker 43.1 46.2  
    Current smoker 56.9 53.8  
Pack years (Mean ± SD)  21.7±12.6 23.2±11.4 0.42 
Duration of COPD(Mean± SD)  15.3±5.7 14.6±6.6 0.36 
Severity as per GOLD (%) Á 0.34 
    Mild 12.7 13.8  
    Moderate 21.9 20.1  
    Severe 45.4 47.6  
    Very severe 20.0 18.5  
No. of Medications (Mean±SD)  7.2±2.1 6.3±1.7 0.68 
Co morbid conditions (%) Á 74 69 0.64 
NB: IG- Intervention group, CG- Control group, SD- standard deviation, FEV1-Forced expiratory volume in one 
second, COPD-Chronic Obstructive Pulmonary Disease, GOLD- Global Initiative for Chronic Obstructive Lung 
Disease; Data were analysed by t test ; ÁData were analysed by Chi square; ¶ FEV1 calculated based on 
spirometry. 
 
Outcomes and estimations 
Medication adherence of COPD patients at different time interval: 
At the baseline, MAQ scores were compared between CG and IG (P>0.05). In IG, MAQ improved 
significantly after the pharmacist intervention at follow-up (P<0.001). The best improvement was noted at 
24 months, giving a picture of wholesome improvement. Medication adherence of COPD patients at 
different time intervals are shown in Table 2. Mean MAQ scores of COPD patients are depicted in Table 
3. 
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Table 2: Medication adherence of COPD patients at different time interval  
 
% Adherence  CG  
n (%) 
IG  
n (%) 
P-Value 
Baseline 
High-Adherence 
Moderate-adherence 
Low-adherence 
 
62 (47.7) 
32 (24.6) 
36 (27.7) 
 
63 (48.5) 
31 (23.8) 
36 (27.7) 
 
0.988 
6 months 
High-Adherence 
Moderate-adherence 
Low-adherent 
 
60 (48.4) 
30 (24.2) 
34 (27.4) 
 
98 (77.1) 
18 (14.2) 
11 (8.7) 
 
< 0.001* 
12 months 
High-Adherence 
Moderate-adherence 
Low-adherence 
 
55 (49.1) 
26 (23.2) 
31 (27.7) 
 
90 (77.6) 
17 (14.7) 
9 (7.8) 
 
< 0.001* 
18 months 
High-Adherence 
Moderate-adherence 
Low-adherence 
 
51 (48.1) 
25 (23.6) 
30 (28.3) 
 
89 (79.5) 
15 (13.4) 
8 (7.1) 
 
< 0.001* 
24 months 
High-Adherence 
Moderate-adherence 
Low-adherence 
 
48 (49) 
23 (23.5) 
27 (27.4) 
 
84 (80.8) 
12 (11.5) 
8 (7.7) 
 
< 0.001* 
NB: CG-Control group, IG-Intervention group, n-Number of patients;  Data were 
analysed by Chi-square; *statistically significant 
 
 
Table 3: Mean MAQ score of COPD patients at different time interval.  
 
Group Baseline  
(95% CI) 
6 months  
(95% CI) 
12 months  
(95% CI) 
18 months 
(95% CI) 
24 months 
(95% CI) 
IG 1.76  
(1.56-1.96) 
1.12  
(0.96-1.28) 
1.09  
(0.92-1.25) 
1.04  
(0.88-1.19) 
0.98  
(0.81-1.15) 
CG 1.80  
(1.60-2.00) 
1.79  
(1.58-2.00) 
1.79  
(1.58-2.01) 
1.80  
(1.57-2.03) 
1.78  
(1.53-2.02) 
NB: CG-Control group, IG-Intervention group, CI-Confidence Interval  
 
Reasons for Non-adherence among COPD Patients: 
At baseline, we found that, stop taking when feel better as the major intentional reason for non-adherence 
in COPD patients (17.6% in CG vs 16.6% in IG). Among unintentional reasons, the carelessness about 
taking medicines (23.5% in CG vs 25.6% in IG) and high cost of medicines (5.9% in CG vs 7.6% in IG) 
were the major reasons for non-adherence. At 24 months follow up, in IG, intentional reasons for non-
adherence were decreased appreciably compared to CG. Table 4 describes various reasons for non-
adherence among COPD patients.  
 
  
8 
 
Table 4: Reasons for Non-adherence among COPD Patients 
 
Reason for non-adherence Baseline 24 Months 
CG (N=68) 
n (%) 
IG (N=66) 
n (%) 
CG (N=50) 
n (%) 
IG (N=21) 
n (%) 
Intentional 
Stop taking medicines when feel better 12 (17.6) 11 (16.6) 8 (16) 1 (4.8) 
Stopping when feeling worse 8 (11.7) 9 (13.6) 6 (12) 1 (4.8) 
Forget to take medicines 7 (10.4) 6 (9.1) 5 (10) 2 (9.5) 
Not beneficial 6 (8.8) 5 (7.6) 5 (10) 1(4.8) 
Fear of side effects 5 (7.4) 3 (4.5) 3 (6) 1(4.8) 
Fear of becoming dependent on treatment 4 (5.9) 4 (6.1) 4 (8) 1(4.8) 
Unintentional 
Carelessness about taking medicines 16 (23.5) 17 (25.6) 12 (24) 2 (9.5) 
High cost of medicines 4 (5.9) 5 (7.6) 3 (6) 6 (28.5) 
Running out of medicines 2 (2.9) 2 (3.1) 2 (4) 2 (9.5) 
Complex dosing regimens 3 (4.4) 2 (3.1) 1 (2) 2 (9.5) 
Old Age 1 (1.5) 2 (3.1) 1 (2) 2 (9.5) 
Total 68 (100) 66 (100) 50 (100) 21 (100) 
NB: CG- Control group, IG-Intervention group, N- Total Number of non-adherent patients, n- Number of patients 
 
Discussion 
 
Pharmacists can prevent drug-related problems and achieve optimal outcomes from drug therapy, 
especially in chronic diseases.36 To the best of our knowledge, this is the first randomized controlled study 
from India that demonstrates the value of a structured pharmacist-led programme on medication 
adherence in COPD patients. Even those few Indian studies that previously evaluated adherence rates in 
patients with COPD are either cross-sectional or observational without considering pharmacist 
interventions. 37-40 Our study findings highlight the importance of patient-education by pharmacist in India. 
 
The suboptimal role played by pharmacists in educating, motivating and counselling patients is evident 
from the fact that COPD patients in India are mostly current smokers while those from Northern Ireland 
are ex-smokers. 31, 37-39 Educational intervention is an economical and feasible strategy, especially in the 
context of the ever-increasing burden of non-communicable disease in resource-poor developing nations 
like India.41 Our results (Table 2 and 3) revealed that, medication adherence can be improved significantly 
(P<0.001) in COPD patients by structured pharmacist-led intervention. Gallefos et al demonstrate that, an 
individualized treatment plan with a self-management training programme, by a nurse / physiotherapist, 
can also improve patient outcomes in COPD within one year. 30 Previous studies by Mahour et al and 
Jarab et al demonstrated that pharmacist-led intervention improved medication adherence in COPD 
patients in Northern Ireland and Jordan respectively.29, 31-32   
 
Patients often lack adequate knowledge about the symptoms and exacerbations of their disease and how 
to deal appropriately in such situations. 42 However, when patients are given an opportunity to identify / 
discuss their concerns about medications and/or life style, fears can be allayed and barriers can be 
identified.  43 This in turns could improve the adherence, given the fact that medication adherence in 
COPD is generally poor. 43 Most frequent reasons for non-adherence in our study, at baseline, in IG, were 
carelessness (25.6%), VWRSSLQJZKHQWKH\µfeel better¶ (16.6%), VWRSSLQJZKHQµIHHOZRUVH¶.6%) and 
forgetting (9.1%). This is consistent with previous studies.6, 44 Intentional reasons for non-adherence 
decreased more appreciably than unintentional reasons, validating the substantial role of structured 
clinical pharmacist-led intervention in our study (Table 4).  
 
Overall, the efforts to improve adherence in COPD patients should focus on maintaining clinical 
significant improvements in health status, prevent exacerbations of the disease and hence reducing the 
associated healthcare costs, rather than merely mandating compliance to healthcare professionals 
instructions.24 It is evident in literature that health professionals FRQWULEXWHWRSDWLHQWV¶SHUFHSWLRQRIWKHLU
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disease, medications and, eventually, their adherence. Previous reports have endorsed the strategies 
employed in our study to improve medication adherence, namely (1) continuous monitoring of care (2) 
explaining the rationale for prescription (3) providing information in both written and verbal forms about 
disease and drug regimens, (4) assessment of medication adherence (5) follow-up supervision and (6) 
participation in self-management programmes.24, 45-46 Consequently, this is an area to focus on in the 
future.  
 
This especially because :+2¶V:RUOG0HGLFLQH6LWXDWLRQUHSRUW indicated that in developing 
countries such as India,  dispensing time is only 60 seconds, with one third of the patients leaving the 
health facility without understanding their prescriptions and up to 50% of dispensed medicines not even 
labelled.47 In developed countries, for example US, Wilson et al. demonstrated that approximately one-
third of patients did not talk to their doctor about their medicines during the last 12 months.48  Over the 
years, several studies showed that a considerable proportion of  patients receive little instructions on how 
to take new medications. 49-50 Overworked physicians and paucity of trained doctors in resource-poor 
settings obligate task-sharing to non-physician healthcare providers like clinical pharmacists, who can 
simplify treatment regimens and enhance compliance. Task sharing is both feasible and less resource 
intensive and would go a long way in the management of COPD based on our and other findings.  
 
Conclusion 
 
Enhancing patient self-efficacy as part of self-management education is important to promote long term 
adherence. Shared decision making during the initial and regular follow-up visits helps to augment the 
partnership between patient and physician, thereby facilitating adherence, improving patient outcomes 
thereby diminish the economic and societal burden associated with COPD. Consequently, pharmacist 
involvement could play a pivotal role in improving medication adherence in COPD. Involving non-
physician health professionals could be the best strategy, for resource-poor nations like India, because 
the current physician-centric healthcare has no emphasis on patient education and counseling. 
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